



News Release

OLON SPA (P&R Group) ACQUIRES RICERCA BIOSCIENCES CHEMICAL DIVISION IN OHIO (USA)

Acquisition strengthens service offering of global CDMO and Generics provider for research and manufacturing

Milan (Italy) – June 9, 2017: Olon S.p.A., a world leading Active Pharmaceutical Ingredients (API) contract development and manufacturing organization (CDMO) and Generics supplier, announced today the acquisition of Ricerca Biosciences' Chemical Division of the contract research (CRO) and CDMO based in Concord, Ohio, USA. This acquisition strengthens the service offering of Olon for the pharmaceutical and biotech industry, and to benefits the Ricerca Biosciences customer base by providing large scale manufacturing capabilities in Europe.

Paolo Tubertini, CEO of Olon, commented, "By acquiring a research and manufacturing base in the US, Olon will have the opportunity to accelerate growth by adding new CDMO projects and to develop new Generic products for the American market." Luca Mantovani, OLON Managing Board member, added, "We are delighted to add Ricerca Biosciences to Olon Group, as this strategic step will broaden our contract research and manufacturing services for all our global customers". No financial details were disclosed.

About Ricerca

Ricerca Biosciences is a US-based CRO supporting the development and manufacture of APIs and performance materials in support clinical supply, market development and commercial distribution. Ricerca's extensive process/synthetic chemistry, analytical chemistry and engineering expertise provides a synergy that excels at first-time scale-ups and subsequent development of safe, reliable, robust and cost effective manufacturing processes. Meeting client needs has been the foundation of Ricerca's business philosophy and is second only to its commitment to safety and regulatory compliance. www.ricerca.com

About Olon Spa

Olon S.p.A. is a world leading Active Pharmaceutical Ingredients (API) manufacturer, with headquarters and five manufacturing facilities located in Italy, and originates from the merger of the previous Solmag and Antibioticos S.p.A.. Olon S.p.A. also acquired INFA Group, an Italian API developer and manufacturer operating worldwide with three manufacturing facilities (2 located in Italy and 1 in Spain) and a trading office in Germany, INFA GmbH. Expertise combined with an internationally-oriented culture lead the company to continually improve its products portfolio and strengthen its presence in the global generics market. Continuous growth is also supported through two subsidiaries: Olon USA Inc. and P&R Shanghai – International Trading Co.. Olon USA Inc. is a wholly owned subsidiary meant to strengthen Olon's position in the U.S. market. www.olonspa.com

For further information:

Luca Mantovani
Executive Vice President – Managing Board Member
Olon Spa
Phone: [+39 02 95233687](tel:+390295233687) - Email: lmantovani@olonspa.it